Expert panel weighs evidence for genetic testing, cholecystectomy, and ERCP in patients with unexplained acute pancreatitis amid limited guideline direction.
To evaluate the management strategies for idiopathic acute pancreatitis (IAP) and the role of genetic testing, cholecystectomy, and ERCP, particularly in the context of varying guidelines.
Approach:
Key Findings:
Genetic testing can identify pathogenic variants in patients with IAP and IRAP, especially in younger patients.
Empiric cholecystectomy may reduce recurrence rates, particularly when occult biliary disease is identified, though evidence is mixed.
Routine ERCP is not recommended for IAP due to associated risks and limited benefits.
Interpretation:
Genetic testing and selective surgical interventions can significantly impact the management of idiopathic acute pancreatitis, but guidelines vary on their application, highlighting the need for individualized approaches.
Limitations:
Genetic testing may face issues like incomplete gene coverage, cost barriers, and psychosocial implications.
Evidence for cholecystectomy is mixed, with small sample sizes affecting statistical significance.
Conclusion:
Careful evaluation and tailored management strategies, including genetic testing and selective surgical interventions, can help reduce recurrence in idiopathic acute pancreatitis, emphasizing the importance of individualized patient assessments.
Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer, and mortality across three large cohorts.
